IVA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
IVA 近期報酬表現
3.88%
Inventiva sa
4.57%
同產業平均
0.12%
S&P500
與 IVA 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TARO | Taro pharmaceutical industries ltd | 3 分 | 5 分 | 4 分 | 1 分 | 1 分 | |
CANF | Can fite biopharma ltd - adr | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
CTLT | Catalent inc | 2 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
OABI | Omniab inc | - | 1 分 | 2 分 | 2 分 | 1 分 | |
CYTH | Cyclo therapeutics inc | 3 分 | 3 分 | 3 分 | 1 分 | 1 分 |
- TARO Taro pharmaceutical industries ltd價值 3 分趨勢 5 分波段 4 分籌碼 1 分股利 1 分查看更多
IVA 公司資訊
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company's pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.